Exciting Participation at the Roth Healthcare Opportunities Conference
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a pioneering company in the exploration of neurodegenerative disorders, is gearing up for an exciting showcase at the Roth Healthcare Opportunities Conference. The president and CEO, Lisa Ricciardi, is set to delve into a panel discussion entitled Frontiers in Neuroscience, which promises to highlight the latest innovations in treating neurological conditions. This significant event occurs on the ninth of October, where key players in healthcare gather to discuss breakthroughs and advancements.
Key Discussions on Neurodegenerative Disease Treatments
During the conference, Ms. Ricciardi will also lead one-on-one investor meetings, providing deep insights into the company's recent achievements and outlining the clinical development plans for their lead candidate, CT1812. This groundbreaking treatment is being developed for Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. Ricciardi will share detailed information on how CT1812 works and its potential impact on these debilitating conditions.
About Cognition Therapeutics and Their Mission
Cognition Therapeutics, Inc. focuses on innovative drug development targeting age-related degenerative diseases affecting the central nervous system and retina. The company is committed to uncovering solutions that modify disease pathways distinctively different from traditional approaches. Their lead candidate, CT1812, is at the forefront of this innovative development, being actively tested in clinical programs aimed at critical diseases such as Alzheimer’s and other related dementias.
Engagement Opportunities at the Conference
The team at Cognition Therapeutics welcomes inquiries from interested investors looking to learn more about their groundbreaking work. Investors wishing to participate should connect with Roth Capital Partners to ensure their place in this pivotal conference. The opportunities presented at the Roth Healthcare Opportunities Conference are invaluable for understanding Cognition's approach to tackling challenging neurodegenerative disorders.
Contact Information for Cognition Therapeutics
If you want to reach out to Cognition Therapeutics for more information or opportunities for engagement, you can do so via email. Here are a few contacts:
- General Information: info@cogrx.com
- Media Inquiries: Casey McDonald at cmcdonald@tiberend.com
- Investor Relations: Mike Moyer at mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is the main focus of Cognition Therapeutics?
Cognition Therapeutics is focused on developing drug therapies for neurodegenerative disorders, including Alzheimer’s disease and related conditions.
Who will be speaking at the Roth Healthcare Opportunities Conference?
Lisa Ricciardi, President and CEO of Cognition Therapeutics, will be participating in a panel discussion at the conference.
What is CT1812?
CT1812 is the lead candidate developed by Cognition Therapeutics for treating Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration.
How can investors meet with Cognition Therapeutics?
Investors interested in engaging with the Cognition team are encouraged to contact Roth Capital Partners to secure their participation at the conference.
Where can I find more information about Cognition Therapeutics?
Detailed information about Cognition Therapeutics and its pipeline can be found on their official website at cogrx.com.
